Pharmaceutical

Type 2 diabetes prevention programs can work at large s...

A new study showed that lifestyle programs — in the real world — can help people...

The apparently strong correlation between biotech stock...

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: German regulator eyes Ozempic expo...

The German drug regulator is considering an export ban on Novo Nordisk's diabete...

STAT+: To get things done fast at FDA: ‘Don’t tell anyb...

The Food and Drug Administration’s top cancer drug regulator doesn’t always ask ...

STAT+: Hospitals say violence against health workers is...

As health care workers face higher risk of violence, hospitals are turning to sy...

STAT+: Life scientists’ flight to biotech labs stalls i...

The seismic shift in researchers from academic to biotech labs is already having...

Opinion: Hospital systems have to decide: Do they want ...

Hospital systems have to decide: Do they want to be Apple or Android?

Opinion: Listen: The true costs of mediocre insurance p...

The true costs of mediocre insurance plans for medical students.

UnitedHealth faces class action lawsuit over algorithmi...

A class action lawsuit was filed against UnitedHealth and a subsidiary alleging ...

Fresh produce access boosts health outcomes among diabe...

Advocates say that programs that treat food as medicine could go a long way towa...

STAT+: ‘I never realized what people go through’: Docto...

After a stage 4 lung cancer diagnosis, former doctor and hospital CEO James Fana...

STAT+: New NIH head says government has fallen behind p...

NIH Director Monica Bertagnolli said it’s a “failure” that enrollment in governm...

What health policies could hitch a ride on a spending b...

What health policies could hitch a ride on a spending bill? We've assembled the ...

A letter from the executive editor: STAT’s investigatio...

A STAT investigation reveals that UnitedHealth pursued a strategy to pressure it...

Nouscom raises $72m in Series C financing round to deve...

Swiss biotech Nouscom has raised €67.5m ($72m) in a Series C funding round co-l...

FDA oversees rise in awarded orphan drug designations f...

Concerns have been raised over the suitability of current FDA-approved treatmen...